Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Blood-based multimodal biomarker models for differentiating early-onset Alzheimer’s disease from frontotemporal dementia: a longitudinal study of early-onset dementia and family members (LEAF) study

H. S. Kwon So Young Moon Mina Hwang H. Kim Sun Min Lee Na-Yeon Jung Hyemin Jang J. Baek Min-Ju Kim Myung-Hoon Han H. Zetterberg K. Blennow Liana G. Apostolova Seong-Ho Koh Eun-Joo Kim
Jul 2026 · Journal of Neurology · Vol 273 · 0 citations · 56 references
Medicine

TL;DR

Plasma p-tau217 and p-tau181 are effective biomarkers for distinguishing biologically defined EOAD from EOFTD and adding NfL, GFAP, and APOE ε4 status further improves the discriminative accuracy for differentiating EOAD from EOFTD.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Jul 2026

Predictive value of plasma p-tau217 for Alzheimer’s dementia compared to other blood-based biomarkers

P-tau217, NfL and GFAP showed strong associations with AD risk, especially within the first 9 years of follow-up, outperforming p-tau181, and over the later years of follow-up, the predictive accuracy of p-tau217 was significantly reduced.

K. Trares, D. Duman, L. Beyer et al. · 0 citations
Open access Sep 2026

Changes in five cerebrospinal fluid and three plasma Alzheimer’s disease biomarkers across increasing brain amyloid-beta and tau pathology burden

A sequential model of biomarker changes across the Alzheimer’s disease neuropathological continuum is supported, with CSF Aβ42/Aβ40 best reflects low/intermediate Aβ burden, while CSF p-tau markers are more closely related to high Aβ and intermediate tau load.

A. Mastrangelo, Simone Baiardi, Edoardo Ruggeri et al. · 0 citations
Aug 2026

Cross-Sectional and Longitudinal Diagnostic Performance of Plasma p-tau217 and p-tau217/Aβ42 in Alzheimer's Disease.

OBJECTIVE Recent studies suggest that combining plasma phosphorylated tau (p-tau) with β-amyloid (Aβ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross-sectional and longitudinal concordance of these markers with Aβ positron emission tomography (PET) positivity remains incompletely underst...

Mingxing Jiang, Guo-Yu Lan, Jiayi Zhu et al. · 0 citations
Open access Jul 2026

Association of total and brain-derived Alzheimer's disease plasma biomarkers with brain amyloid deposition in a community-based sample

In a community-based sample, BD-p-tau217 emerged as the plasma biomarker most strongly associated with brain A{beta} deposition, although this association may be attenuated in the presence of moderate/severe kidney dysfunction or kidney failure.

Muge Akinci, Froogh Aziz, D. Guzman et al. · 0 citations
Open access Jul 2026

Relative importance of blood-based biomarkers for Alzheimer’s disease-specific neurodegeneration and cognitive decline

A stratified approach based on amyloid status is essential for the optimal application of blood-based biomarkers in monitoring disease progression and evaluating therapeutic efficacy in future clinical trials and precision medicine.

Keun You Kim, Hyunsun Ham, E. Yoon et al. · 0 citations
Open access Jul 2026

Serum p-Tau217 and apolipoprotein E as potential biomarkers for Alzheimer's disease severity: a case-control study

Increased serum p-tau217 and decreased ApoE levels were significantly associated with greater AD severity, suggesting that both biomarkers may serve as complementary noninvasive indicators of disease severity in Alzheimer’s disease.

Ahmed Kadom Kalaf, Khawla A. Shemran, Waleed Azeez AlAmeedy · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.